Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Prime Medicine, Inc.NASDAQ: PRME

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) remains negative

Q1 FY2026 deferred revenue (non-current) was $0, compared with $72.66M a year earlier.

Context

  • Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q1 FY2026, down 22.1 pp from a year earlier.
  • Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue (non-current) keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$72.66M-100.0% since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Deferred Revenue (Non-current) vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's Mar 2026 deferred revenue (non-current) of $0 is the 3rd highest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the 3rd highest of 6, against a peer median of -100.0%.
  • Deferred revenue (non-current) amounts to 0.0% of total assets for PRME, versus a peer median of 0.0%.
PRME Competitors Peer median
Deferred Revenue (Non-current) for PRME and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EDITEditas Medicine, Inc.Mar 2026$44.51M -57.1%-9.8%29.8%
CRBUCaribou Biosciences, Inc.Mar 2026$1.65M -37.1%-52.1%1.1%
PRMEPrime Medicine, Inc.Mar 2026$0 -100.0%—0.0%
CRSPCRISPR Therapeutics AGSep 2026$0 -100.0%—0.0%
BEAMBeam Therapeutics Inc.Jun 2026$0 -100.0%—0.0%
NTLAIntellia Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
DSGNDesign Therapeutics, Inc.Mar 2026$0 ——0.0%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding PRME) $0-100.0%-31.0%0.0%

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents185.42M187.62M41.57M182.48M63.03M
Short-term Investments84.2M106.3M80.09M7.97M114.65M
Net Receivables00000
Inventory00000
Other Current Assets0246K2.25M14.67M3.61M
Total Current Assets270.58M296.62M142.98M211.89M181.29M
Property, Plant & Equipment (Net)15.68M48.55M36.6M71.56M146.75M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets15.6M15.14M14.28M14.06M14.69M
Total Non-current Assets31.28M63.7M50.88M85.62M161.44M
Total Assets301.86M360.31M193.85M297.51M342.73M
Account Payables1.44M4.33M19.54M11.35M8.89M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0007.09M7.82M
Other Current Liabilities14.66M6.98M10.91M6.93M9.04M
Total Current Liabilities57.98M26.71M56.42M37.96M37.45M
Long-term Debt0000108.29M
Deferred Tax Liabilities1.24M279K000
Deferred Revenue (Non-current)00063.22M0
Other Non-current Liabilities0006M76.13M
Total Non-current Liabilities4.31M17.33M4.36M106.4M184.42M
Total Liabilities62.3M44.04M60.78M144.36M221.87M
Common Stock1K2K2K2K2K
Retained Earnings(171.38M)(293.2M)(491.33M)(687.21M)(888.35M)
Accumulated OCI(27K)(384K)(15K)1K82K
Other Stockholders Equity00000
Minority Interest00000
Total Equity239.56M316.27M133.07M153.15M120.87M
Total Debt10.41M28.75M13.63M40.79M116.43M
Net Debt(175.01M)(158.88M)(27.94M)(141.68M)53.4M

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.